Medicare Enrolled

Dr. Mohamed Altattan, M.D.

Rheumatology · Royal Oak, MI
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
30701 WOODWARD AVE STE 314S, Royal Oak, MI 48073
2489559229
In practice since 2015 (11 years)
NPI: 1477932093 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Altattan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Altattan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Altattan

Dr. Mohamed Altattan is a rheumatology specialist in Royal Oak, MI, with 11 years of NPI registration. Based on federal Medicare data, Dr. Altattan performed 580 Medicare services across 412 unique beneficiaries.

Between the years covered by Open Payments, Dr. Altattan received a total of $5,445 from 23 pharmaceutical and/or device companies across 218 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Altattan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 11 years in practice ▲ Top 49% volume in MI $5,445 industry payments

Medicare Practice Summary

Medicare Utilization ↗
580
Medicare services
Top 49% in MI for rheumatology
412
Unique beneficiaries
$89
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~53 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Hospital follow-up visit, moderate complexity
Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service.
234 $60 $151
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
96 $129 $806
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
95 $88 $251
Hospital discharge management, 30+ min
This service covers the care provided by a physician or qualified healthcare professional on the day a patient is discharged from the hospital. It requires more than 30 minutes of total time spent on the day of discharge.
47 $85 $253
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
30 $105 $270
New patient office visit, complex (60-74 min) 27 $179 $521
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
26 $138 $415
Hospital discharge day management, 30 minutes or less
This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less.
25 $61 $205
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$5,445
Total received (2018-2024)
Avg $1,089/year across 5 years
Top 40% in MI for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
23
Companies
218
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,931 (72.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,247 (22.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$267 (4.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,283
2023
$308
2022
$413
2021
$335
2018
$106

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$1,247
Amgen Inc.
$606
UCB, Inc.
$562
ABBVIE INC.
$294
Novartis Pharmaceuticals Corporation
$222
E.R. Squibb & Sons, L.L.C.
$209
Fresenius Kabi USA, LLC
$206
Lilly USA, LLC
$175
AstraZeneca Pharmaceuticals LP
$147
PFIZER INC.
$139
GlaxoSmithKline, LLC.
$92
ANI Pharmaceuticals, Inc.
$80
Mallinckrodt Hospital Products Inc.
$77
SOBI, INC
$62
GENZYME CORPORATION
$55
Kiniksa Pharmaceuticals International, plc
$53
Aurinia Pharma U.S., Inc.
$30
Genentech USA, Inc.
$25
Top 3 companies account for 56.4% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,530
Amgen Inc.
$635
UCB, Inc.
$562
ABBVIE INC.
$419
Novartis Pharmaceuticals Corporation
$267
AbbVie Inc.
$265
Lilly USA, LLC
$228
E.R. Squibb & Sons, L.L.C.
$209
Fresenius Kabi USA, LLC
$206
PFIZER INC.
$196
AstraZeneca Pharmaceuticals LP
$147
Mallinckrodt Hospital Products Inc.
$117
GlaxoSmithKline, LLC.
$110
Relypsa, Inc.
$106
Smith+Nephew, Inc.
$103
ANI Pharmaceuticals, Inc.
$80
SOBI, INC
$62
GENZYME CORPORATION
$55
Kiniksa Pharmaceuticals International, plc
$53
Aurinia Pharma U.S., Inc.
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$25
Genentech USA, Inc.
$25
Horizon Therapeutics plc
$16
Top 3 companies account for 50.1% of all-time payments
Associated products mentioned in payments ›
ACTHAR · Actemra · Arcalyst · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Enbrel · GRAFIX PL · HUMIRA · IDACIO · ILARIS · KEVZARA · KINERET · KRYSTEXXA · LUPKYNIS · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · REMICADE · RINVOQ · SAPHNELO · SIMPONI ARIA · SKYRIZI · TALTZ · TAVNEOS · TREMFYA · Veltassa · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (72%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Royal Oak?
Compare rheumatologists in the Royal Oak area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
63
Per 100K population
5.0
County median income
$95,296
Nearest hospital
BEAUMONT HOSPITAL ROYAL OAK
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Altattan is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Altattan experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Altattan performed 234 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Altattan receive payments from pharmaceutical companies?
Yes. Dr. Altattan received a total of $5,445 from 23 companies across 218 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Altattan's costs compare to other rheumatologists in Royal Oak?
Dr. Altattan's average Medicare payment per service is $89. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Altattan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →